BioNxt Solutions Prepares for Human Bioequivalence Study For MS
23.4.2025 03:05:00 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Ondas to Launch LADOS, a Layered Autonomous Defense Operational C2 Layer, at Eurosatory 202610.6.2026 14:30:00 CEST | Press release
LADOS connects Ondas' systems, including sensors, effectors, autonomous platforms, and command units, into one immediate operational core for integrated missions and serves as a critical systems-of-systems command-and-control layer LADOS is part of Ondas' multi-domain software architecture that includes SkyWeaver, a Palantir-powered Agentic AI layer for Multi-Domain Mission Autonomy and long-range ISR-to-assault applications The system will be officially launched at Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions WEST PALM BEACH, FL / ACCESS Newswire / June 10, 2026 / Ondas Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous drone and advanced defense technologies, today announced that it will officially launch LADOS - a Layered Autonomous Defense Operational C2 System, during Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions. LADOS serves as
Agassi Sports Entertainment Signs Tennis Coaching Icon Darren Cahill to Expand Global Coaching, Content and Technology Initiatives10.6.2026 14:30:00 CEST | Press release
Former coach to Andre Agassi joins ASE to support the Company's Agassi Intelligence platform, premium content initiatives and global growth strategy LAS VEGAS, NV / ACCESS Newswire / June 10, 2026 / Agassi Sports Entertainment Corp. (OTCID:AASP) ("ASE" or the "Company"), a sports, media, and technology platform focused on the global racket sports ecosystem and built around the iconic brands of Andre Agassi and Stefanie Graf, today announced that it has entered into a name and likeness license agreement with renowned tennis coach Darren Cahill. As a member of the team, Cahill will collaborate with ASE across a range of strategic initiatives, including the Company's previously announced Agassi Intelligence technology platform being developed in partnership with IBM, original content creation, media opportunities and other global growth initiatives designed to expand access to world-class coaching and deepen fan engagement across racket sports. Cahill, a former professional player and one
Leggett & Platt Automotive Launches New Brand Identity: Leggett Dynamics10.6.2026 12:50:00 CEST | Press release
ACCELERATES INNOVATION & GROWTH IN COMFORT, MOTION & SOFTWARE INTEGRATED SYSTEMS DETROIT, MI / ACCESS Newswire / June 10, 2026 / Leggett & Platt Automotive today announced the launch of its new brand identity, "Leggett Dynamics", and tagline "eMotion & Comfort for everyone, everywhere, every day" signaling a strategic shift to accelerate innovation and growth in comfort and motion systems for automotive, adjacent and diversified markets. Megatrend & Consumer Shifts "Leggett Dynamics creates experiences where comfort and motion feel effortless, intelligent, personalized and instinctive across all aspects of life. This positions us well in the market in terms of megatrends as well as anticipating and proactively innovating for future expectations," said Marinela Cirstea, President of Leggett Dynamics. According to Cirstea, comfort and motion are at the epicenter of converging megatrends and shifting consumers' priorities toward personalized experiences, health and wellness, plus instant
Camino Intercepts High-Grade Copper With 76.2m at 0.88% Cu Including 16.25m at 2.67% Cu and 6.82g/t Ag at Costa de Cobre in Peru; All Five Reported Drill Holes Intersect Strong Copper Mineralization10.6.2026 12:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / June 10, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce the exploration results from Phase 2 of the recent drilling campaign at its Costa de Cobre project ("Costa de Cobre" or the "Project" (formerly known as "Los Chapitos"(1)) in Peru. Camino completed five drill holes along the Diva trend corridor, where drilling activities focused on the Adriana target with the objective of expanding the known mineralized body and improving the understanding of the scale and continuity of the mineralized system. The maximum drill hole depth was 260 metres and all five drill holes intercepted strong copper mineralization and spanned a strike length of approximately 400 metres. Key highlights of recent Costa de Cobre drill holes: Adriana: DCH-131: 69.8 m @ 0.47% Cu & 4.17 g/t Ag, including 32.0 m @ 0.75% Cu & 6.50 g/t Ag, and 9.75m @ 1.25% Cu & 6.46 g/t Ag, including 3.90 m @ 2.99% Cu & 15.63 g/t Ag Adrian
From Retrofit to AI: Akkodis Strengthens Digital Innovation Through Industrial Aerospace Applications at ILA Berlin 202610.6.2026 06:45:00 CEST | Press release
At ILA Berlin 2026, Akkodis will showcase concrete applications in digital engineering, AI-driven analytics and industrial execution across the entire aerospace lifecycle - from initial digital design to real-world aerospace applications. BERLIN, DE / ACCESS Newswire / June 10, 2026 / Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, demonstrates how digital development, artificial intelligence and industrial execution come together to bring new solutions into aerospace applications faster at ILA Berlin 2026. Image: Akkodis at ILA Berlin 2026. Source: AkkodisIn 2026, the aerospace and defense sector is being shaped by strong growth and sustained long-term demand, supported by continued investment in innovation and next-generation technologies. At the same time, increasing pressures on efficiency, availability and sustainability are driving a shift toward solutions that can be rapidly integrated and scaled. At the center of Akkodis' presence is a n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom